Method for discrimination of metaplasias from neoplastic or preneoplastic lesions
The present invention relates to a method for discrimination of p16.sup.INK4a overexpressing metaplasias from neoplastic or preneoplastic p16.sup.INK4a overexpressing lesions by determination of the level of high risk HPV encoded gene-products such as e.g. HPV E2 and/or HPV E7 molecules in biological samples in the course of cytological testing procedures. The method thus enables for reduction of false positive results in the p16.sup.INK4a based detection of anogenital lesions in cytological testing procedures.
1. A method for preparing a uterine cervical cytology sample for discriminating metaplasias from neoplastic or preneoplastic lesions by cytological testing, the method comprising immunochemically double staining the sample with an anti-p16 INK4a antibody and with an antibody immunoreactive with a polypeptide encoded by an E2 gene of a high risk human papillomavirus (hr-HPV) in a manner that permits simultaneous detection of p16 INK4a and the polypeptide encoded by the E2 gene of the hr-HPV.
2. The method of claim 1 , wherein the sample is deposited on a microscope slide in a form of a smear, a monolayer, or a thin layer.
3. The method of claim 1 , wherein the hr-HPV is selected from the group consisting of HPV 16, HPV 18, HPV 31, HPV 33, HPV 35, HPV 39, HPV 45, HPV 51, HPV 52, HPV 56 and HPV 58.
4. The method of claim 1 , wherein the hr-HPV is selected from the group consisting of HPV 16, HPV 18, HPV 39, and HPV 45.
5. The method of claim 1 , wherein the hr-HPV is HPV 16.
6. A method for preparing a uterine cervical cytology sample for discriminating metaplasias from neoplastic or preneoplastic lesions by cytological testing, the method comprising immunochemically double staining the sample with an anti-p16 INK4a antibody and with an antibody immunoreactive with a polypeptide encoded by an L1 gene of a high risk human papillomavirus (hr-HPV) in a manner that permits simultaneous detection of p16 INK4a and the polypeptide encoded by the L1 gene of the hr-HPV.
7. The method of claim 6 , wherein the sample is deposited on a microscope slide in a form of a smear, a monolayer, or a thin layer.
8. The method of claim 6 , wherein the hr-HPV is selected from the group consisting of HPV 16, HPV 18, HPV 31, HPV 33, HPV 35, HPV 39, HPV 45, HPV 51, HPV 52, HPV 56 and HPV 58.
9. The method of claim 6 , wherein the hr-HPV is selected from the group consisting of HPV 16, HPV 18, HPV 39, and HPV 45.
10. The method of claim 6 , wherein the hr-HPV is HPV 16.